Antibody therapy for acute myeloid leukaemia
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Summary: Novel therapies with increased efficacy and decreased toxicity are desperately needed for the treatment of acute myeloid leukaemia (AML). The anti CD33 immunoconjugate, gemtuzumab ozogamicin (GO), was withdrawn with concerns over induction mortality and lack of efficacy. However a number of recent trials suggest that, particularly in AML with favourable cytogenetics, GO may improve overall survival. This data and the development of alternative novel monoclonal antibodies (m A b) have renewed interest in the area. Leukaemic stem cells (LSC) are identified as the subset of AML blasts that reproduces the leukaemic phenotype upon transplantation into immunosuppressed mice. AML relapse may be caused by chemoresistant LSC and this has refocused interest on identifying and targeting antigens specific for LSC. Several mA b have been developed that target LSC effectively in xenogeneic models but only a few have begun clinical evaluation. Antibody engineering may improve the activity of potential new therapeutics for AML. The encouraging results seen with bispecific T cell‐engaging mA b‐based molecules against CD19 in the treatment of B‐cell acute lymphobalstic leukaemia, highlight the potential efficacy of engineered antibodies in the treatment of acute leukaemia. Potent engineered mA b, possibly targeting novel LSC antigens, offer hope for improving the current poor prognosis for AML.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625 · cited 1×
“Bevacizumab is a humanized mAb, which neutralizes all human VEGF-A isoforms (Ferrara et al, 2004).”
BackgroundClonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D., et al. (2012) · Nature · doi:10.1038/nature10738 · Cited by 1,993
Majeti, R., Chao, M. P., Alizadeh, A. A., Pang, W. W., Jaiswal, S., Gibbs, K. D., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.045 · Cited by 1,752 · cited 2×
“Nonetheless, there is higher expression of CD47 in the LSC compartment than in normal HSC and increased expression of CD47 is a poor prognostic factor in patients with AML (Majeti et al, 2009).”
BackgroundBispecific T-Cell Engaging Antibodies for Cancer Therapy
Baeuerle, P. A., & Reinhardt, C. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0547 · Cited by 592 · cited 1×
“The bispecific T-cell engager (BiTE) molecules combine a CD3 scFv with an antigen-specific scFv to recruit cytotoxic T cells to cancer cells (Baeuerle & Reinhardt, 2009).”
BackgroundFauriat, C., Just-Landi, S., Mallet, F., Arnoulet, C., Sainty, D., Olive, D., & Costello, R. T. (2007) · Blood · doi:10.1182/blood-2005-08-027979 · Cited by 380
Van Tendeloo, V. F., Van de Velde, A., Van Driessche, A., Cools, N., Anguille, S., Ladell, K., Gostick, E., Vermeulen, K., Pieters, K., Nijs, G., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008051107 · Cited by 377
Edris, B., Weiskopf, K., Volkmer, A. K., Volkmer, J.-P., Willingham, S. B., Contreras-Trujillo, H., Liu, J., Majeti, R., West, R. B., Fletcher, J. A., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121629109 · Cited by 258
Cited by
Döhner, H., Weisdorf, D. J., & Bloomfield, C. D. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1406184 · Cited by 3,306
Altered Tumor-Cell Glycosylation Promotes Metastasis
Häuselmann, I., & Borsig, L. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00028 · Cited by 382
Acute Myeloid Leukemia: A Concise Review
Saultz, J., & Garzon, R. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5030033 · Cited by 342
Hematopoietic stem cell transplantation-50 years of evolution and future perspectives
Henig, I., & Zuckerman, T. (2014) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10162 · Cited by 209
Stress and non-stress roles of inflammatory signals during HSC Emergence and maintenance
Clapes, T., Lefkopoulos, S., & Trompouki, E. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00487 · Cited by 62
Metadata
- Authors
- Gasiorowski, R. E., Clark, G. J., Bradstock, K., & Hart, D. N. J.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2013-12-10
- Volume
- 164
- Issue
- 4
- Pages
- 481-495
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2023266767
- Cited by
- 49
- References
- 7
- FWCI
- 4.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antibody therapy for acute myeloid leukaemia. https://app.cochat.ai/papers/10.1111/bjh.12691
- The paper
- Gasiorowski, R. E., Clark, G. J., Bradstock, K., & Hart, D. N. J. (2014). Antibody therapy for acute myeloid leukaemia. British Journal of Haematology. https://doi.org/10.1111/bjh.12691
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.